These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2995172)

  • 21. A universal virus inactivant for decontaminating blood and biopharmaceutical products.
    Brown F; Meyer RF; Law M; Kramer E; Newman JF
    Dev Biol Stand; 1999; 99():119-30. PubMed ID: 10404883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity.
    Capelle MA; Brügger P; Arvinte T
    Vaccine; 2005 Feb; 23(14):1686-94. PubMed ID: 15705473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Foot-and-mouth virus component responsible for immunogenesis].
    Salazhov EL; Ivanov VS
    Veterinariia; 1970 Sep; 9():38-40. PubMed ID: 4323895
    [No Abstract]   [Full Text] [Related]  

  • 24. [Safety of foot-and-mouth disease vaccines in cell cultures].
    Tekerlekov P; Dilovski M; Gergov P; Nikolova E
    Vet Med Nauki; 1982; 19(1):21-5. PubMed ID: 6287707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural differences between foot-and-mouth disease and poliomyelitis viruses influence their inactivation by aziridines.
    Burrage T; Kramer E; Brown F
    Vaccine; 2000 May; 18(22):2454-61. PubMed ID: 10738103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The elution of foot-and-mouth disease virus from vaccines adjuvanted with aluminium hydroxide and with saponin.
    Doel TR; Staple RF
    J Biol Stand; 1982 Jul; 10(3):185-95. PubMed ID: 6290497
    [No Abstract]   [Full Text] [Related]  

  • 27. [Adsorption of antigens K88 and K99 on aluminum hydroxide gel].
    Kapurdova M; Petkov M; Marchev N
    Vet Med Nauki; 1987; 24(1):15-8. PubMed ID: 3303654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Past and present vaccine development strategies for the control of foot-and-mouth disease.
    Balamurugan V; Kumar RM; Suryanarayana VV
    Acta Virol; 2004; 48(4):201-14. PubMed ID: 15745043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple variants in foot-and-mouse disease virus (FMDV) populations: the Achilles heel for peptide and rec. DNA vaccines?
    Barteling SJ; Woortmeyer R
    Dev Biol Stand; 1987; 66():511-21. PubMed ID: 3034708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pressure-inactivated FMDV: a potential vaccine.
    Ishimaru D; Sá-Carvalho D; Silva JL
    Vaccine; 2004 Jun; 22(17-18):2334-9. PubMed ID: 15149793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [pH inactivation of the foot-and-mouth disease virus].
    Olechnowitz AF; Engler E
    Arch Exp Veterinarmed; 1970; 24(2):461-71. PubMed ID: 4325728
    [No Abstract]   [Full Text] [Related]  

  • 32. [The inactivation of foot-and-mouth disease virus by ethylethyleneimine and the use of the inactivated virus in the preparation of vaccines].
    Bauer K
    Zentralbl Bakteriol Orig; 1970 Apr; 213(3):285-97. PubMed ID: 4318509
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions.
    Amadori M; Barei S; Melegari M; Panina GF
    Vaccine; 1987 Sep; 5(3):219-22. PubMed ID: 2823495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of foot-and-mouth disease virus vaccine strains by activation of virus-associated endonuclease.
    Scodeller EA; Lebendiker MA; Dubra MS; Crespo OA; Basarab O; La Torre JL; Vasquez C
    J Gen Virol; 1984 Sep; 65 ( Pt 9)():1567-73. PubMed ID: 6088682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of amino acids in the formaldehyde inactivation of the foot-and-mouth disease virus].
    Ulupov NA
    Veterinariia; 1974 Sep; (9):38-9. PubMed ID: 4377336
    [No Abstract]   [Full Text] [Related]  

  • 36. Detection of virus infection-associated antigen and 3D antibodies in cattle vaccinated against foot and mouth disease.
    O'Donnell VK; Smitsaart E; Cetra B; Duffy S; Finelli J; Boyle D; Draghi G; Fondevila N; Schudel AA
    Rev Sci Tech; 1997 Dec; 16(3):833-40. PubMed ID: 9567309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans.
    Kistner O; Barrett N; Brühmann A; Reiter M; Mundt W; Savidis-Dacho H; Schober-Bendixen S; Dorner F; Aaskov J
    Vaccine; 2007 Jun; 25(25):4845-52. PubMed ID: 17509734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies on the suitability of tissue culture neutralization tests in the government etesting of adsorbed foot-and mouth disease vaccines. 1. The content of neutralizing antibody in the serum of cattle after vaccination with adsorbed vaccine against type O2 virus in comparison with the direct immunity testing in cattle].
    Rüting E; Seils H; Weyhe D; Benndorf E
    Arch Exp Veterinarmed; 1969; 23(4):827-38. PubMed ID: 4319494
    [No Abstract]   [Full Text] [Related]  

  • 39. Experiments on an early protection against foot-and-mouth disease virus.
    Liebermann HT; Thalmann G; Bartels T; Nöckler A
    Acta Virol; 1993; 37(2-3):181-3. PubMed ID: 8105663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and potency aspects in the preparation of an experimental HBsAg vaccine.
    Thomssen R; Gerlich WH; Böttcher U; Legler K; Ritter S; Stibbe W; Weinmann W; Klinge O; Pfeifer U
    Dev Biol Stand; 1983; 54():23-31. PubMed ID: 6228464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.